Clinical Scorecard: Implant Restores Central Vision in GA
At a Glance
| Category | Detail |
|---|---|
| Condition | Geographic Atrophy (GA) due to Age-Related Macular Degeneration (AMD) |
| Key Mechanisms | Subretinal photovoltaic implant stimulates inner retinal neurons to restore visual signal transmission. |
| Target Population | Patients with advanced geographic atrophy involving the fovea and baseline visual acuity of at least 1.2 logMAR. |
| Care Setting | Multicenter clinical trial across 17 sites in 5 European countries. |
Key Highlights
- 26 of 32 evaluable participants achieved clinically meaningful improvement in visual acuity at 12 months.
- Participants reported reading letters and numbers at home, with 69% expressing medium to high satisfaction.
- The PRIMA system allows for simultaneous natural and prosthetic vision with adjustable zoom settings.
Guideline-Based Recommendations
Diagnosis
- Assess visual acuity and confirm bilateral GA involving the fovea.
Management
- Consider the PRIMA implant for eligible patients to restore central vision.
Monitoring & Follow-up
- Evaluate visual acuity and monitor for adverse events post-implantation.
Risks
- Monitor for serious adverse events such as ocular hypertension and retinal breaks.
Patient & Prescribing Data
Participants aged 78.9 years on average, with advanced GA.
The PRIMA implant demonstrated a mean improvement of 0.49 logMAR at 12 months.
Clinical Best Practices
- Utilize advanced intraoperative imaging techniques for implantation.
- Ensure thorough patient education on the use of the PRIMA glasses and device.
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
